0.7513
price up icon7.33%   0.0513
after-market Dopo l'orario di chiusura: .73 -0.0213 -2.84%
loading
Precedente Chiudi:
$0.70
Aprire:
$0.6947
Volume 24 ore:
371.42K
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.60M
Reddito:
$4.70M
Utile/perdita netta:
$-4.99M
Rapporto P/E:
-0.117
EPS:
-6.42
Flusso di cassa netto:
$-5.29M
1 W Prestazione:
+22.52%
1M Prestazione:
-37.39%
6M Prestazione:
-70.88%
1 anno Prestazione:
-64.89%
Intervallo 1D:
Value
$0.6816
$0.77
Intervallo di 1 settimana:
Value
$0.61
$0.77
Portata 52W:
Value
$0.4519
$7.20

Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile

Name
Nome
Salarius Pharmaceuticals Inc
Name
Telefono
346-772-0346
Name
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Name
Dipendente
2
Name
Cinguettio
@SalariusPharma
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SLRX's Discussions on Twitter

Confronta SLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLRX
Salarius Pharmaceuticals Inc
0.7513 1.49M 4.70M -4.99M -5.29M -6.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-04-27 Iniziato Ladenburg Thalmann Buy

Salarius Pharmaceuticals Inc Borsa (SLRX) Ultime notizie

pulisher
Jul 24, 2025

Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Salarius Pharmaceuticals Inc. stockLightning-fast capital gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Nigeria

Jul 21, 2025
pulisher
Jul 16, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative

Jul 14, 2025
pulisher
Jul 14, 2025

SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan

Jul 14, 2025
pulisher
Jul 10, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks

Jul 08, 2025
pulisher
Jun 18, 2025

Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq

Jun 17, 2025

Salarius Pharmaceuticals Inc Azioni (SLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):